Robert W. Baird Initiates Coverage on CVS Health (NYSE:CVS)

Investment analysts at Robert W. Baird began coverage on shares of CVS Health (NYSE:CVSGet Free Report) in a report released on Thursday, Marketbeat Ratings reports. The firm set a “neutral” rating and a $61.00 price target on the pharmacy operator’s stock. Robert W. Baird’s price objective suggests a potential upside of 13.55% from the stock’s current price.

A number of other equities research analysts also recently weighed in on CVS. Argus dropped their target price on CVS Health from $100.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. StockNews.com lowered shares of CVS Health from a “buy” rating to a “hold” rating in a research report on Thursday, February 15th. UBS Group cut CVS Health from a “buy” rating to a “neutral” rating and cut their price target for the company from $85.00 to $60.00 in a research note on Thursday, May 2nd. The Goldman Sachs Group decreased their price target on CVS Health from $85.00 to $74.00 and set a “buy” rating on the stock in a research report on Thursday, May 2nd. Finally, Bank of America reduced their price objective on shares of CVS Health from $95.00 to $77.00 and set a “buy” rating on the stock in a research note on Thursday, May 2nd. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $76.00.

Get Our Latest Stock Analysis on CVS Health

CVS Health Price Performance

NYSE:CVS opened at $53.72 on Thursday. The firm’s fifty day moving average price is $65.70 and its two-hundred day moving average price is $71.64. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.81 and a quick ratio of 0.61. The company has a market cap of $67.44 billion, a P/E ratio of 9.44, a P/E/G ratio of 0.51 and a beta of 0.56. CVS Health has a one year low of $52.77 and a one year high of $83.25.

CVS Health (NYSE:CVSGet Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.69 by ($0.38). CVS Health had a return on equity of 13.53% and a net margin of 2.03%. The company had revenue of $88.44 billion for the quarter, compared to analyst estimates of $89.33 billion. During the same quarter last year, the business earned $2.20 earnings per share. The company’s revenue was up 3.7% on a year-over-year basis. Equities analysts expect that CVS Health will post 7.02 earnings per share for the current year.

Insider Buying and Selling at CVS Health

In related news, Director Edward J. Ludwig acquired 1,000 shares of the stock in a transaction dated Thursday, May 2nd. The stock was bought at an average price of $53.88 per share, for a total transaction of $53,880.00. Following the purchase, the director now directly owns 21,630 shares of the company’s stock, valued at approximately $1,165,424.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.24% of the company’s stock.

Institutional Investors Weigh In On CVS Health

Several hedge funds and other institutional investors have recently bought and sold shares of CVS. Vanguard Group Inc. grew its stake in CVS Health by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 117,696,285 shares of the pharmacy operator’s stock valued at $9,293,299,000 after acquiring an additional 533,659 shares during the period. Capital World Investors raised its holdings in CVS Health by 8.0% during the first quarter. Capital World Investors now owns 43,776,874 shares of the pharmacy operator’s stock worth $3,491,643,000 after buying an additional 3,232,172 shares during the last quarter. Capital International Investors lifted its stake in shares of CVS Health by 12.5% in the first quarter. Capital International Investors now owns 37,917,923 shares of the pharmacy operator’s stock valued at $3,024,334,000 after buying an additional 4,226,225 shares in the last quarter. FMR LLC increased its position in shares of CVS Health by 29.1% during the third quarter. FMR LLC now owns 27,487,238 shares of the pharmacy operator’s stock worth $1,919,159,000 after acquiring an additional 6,194,441 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of CVS Health by 2.2% in the 3rd quarter. Northern Trust Corp now owns 14,214,296 shares of the pharmacy operator’s stock worth $992,442,000 after acquiring an additional 305,564 shares during the last quarter. 80.66% of the stock is owned by institutional investors.

About CVS Health

(Get Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Recommended Stories

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.